Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
Predictive Model Forecasts Advanced NSCLC Outcomes

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com
FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi
Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com
Legal Navigation Services Key to Addressing Disparities in Cancer Care

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
August 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
April 9th 2025

How AI, Data Analytics, and Outcomes-Based Contracts Are Shaping Health Care: Laura Bobolts, PharmD, BCOP

Pearl Steinzor Laura R. Bobolts, PharmD, BCOP
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, shares how health care leaders are advancing value-based care through improved data strategies, real-world evidence, and AI-driven efficiencies, without losing the human touch.
Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg
April 9th 2025

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

Giuliana Grossi
New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
AJMC
April 4th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

Galen Shearn-Nance, BS Rishi R. Sachdev, BS Long Vu, MS Weichuan Dong, PhD Alberto J. Montero, MD, MBA Siran M. Koroukian, PhD Johnie Rose, MD, PhD
This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com
April 2nd 2025

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

Hayden E. Klein
After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.
Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS
April 1st 2025

Long-Term Effects of COVID-19 Disruptions on Cancer Care Still Unfolding: Dan Nardi, MS

Brooke McCormick Dan Nardi, MS
The long-term impact of disruptions in oncology care during the COVID-19 pandemic will become more apparent in the coming years, according to Dan Nardi, MS, of Reimagine Care.
Round FDA approval stamp in blue ink | Image Credit: © Surendra - stock.adobe.com
March 31st 2025

FDA Approves Durvalumab Combo for Muscle-Invasive Bladder Cancer

Maggie L. Shaw
The approval follows the December 2024 priority review designation for this perioperative immunotherapy regimen for patients fighting muscle-invasive bladder cancer.
FDA Approved. | Image Credit: wladimir1804 - stock.adobe.com
March 26th 2025

FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors

Giuliana Grossi
With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
March 25th 2025

3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

Hayden E. Klein
One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more sensitive to chemotherapy but had worse overall survival.
Cathy Eng, MD, FACP, FASCO
March 24th 2025

Elevating Cancer Care Through Personalized Treatment

Maggie L. Shaw Cathy Eng, MD, FACP, FASCO
In this discussion with Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, she illustrates how Vanderbilt works to specify each individual patient’s cancer care regimen and treatment path.
Estrogen | Image credit: Debalina - stock.adobe.com
March 20th 2025

Estrogen Therapy May Increase Risk of 3 Skin Cancers

Hayden E. Klein
Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.
Karen Winkfield, MD, PhD
March 19th 2025

Expanding Access to Clinical Trials Through Community Partnerships

Maggie L. Shaw Karen Winkfield, MD, PhD
Karen Winkfield, MD, PhD, addresses the importance of meeting patients where they are to expand clinical trial participation and remove barriers to trial access.
Texas Oncology logo | Image: Texas Oncology
March 18th 2025

Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot

Mary Caffrey Rose McNulty
Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
March 17th 2025

Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year

Mary Caffrey
As St. Patrick's Day brings global celebrations involving alcohol, Ireland looks forward to rethinking excess consumption with a new tool set to arrive next year: the world's most comprehensive alcohol warning label.
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
March 15th 2025

How Do Infusion Pharmacies Support Financial Sustainability in Oncology?

Hayden E. Klein Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Jorge García, PharmD, MS, MBA, MHA, highlights the need for infusion pharmacy optimization to sustain oncology care amid rising costs and evolving value-based reimbursement models.
Doctor screening patient for skin cancer | Image credit: Seventyfour – stock.adobe.com
March 14th 2025

Patients Prefer AI in Skin Cancer Screening as an Assistive Tool, Not a Replacement

Hayden E. Klein
Patients expressed concern that overreliance on artificial intelligence (AI) could lead to clinicians losing their skills, both medical and interpersonal.
The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle
March 9th 2025

The Weapons of Getting Paid: Bringing Data, Technology, and Advocacy to the Battle

Mary Caffrey
Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.
Doctor conducting a skin cancer check | Image credit: InsideCreativeHouse - stock.adobe.com
March 6th 2025

Image-Guided Superficial Radiation Therapy Safe, Effective Treatment for Nonmelanoma Skin Cancer: Expert Panel

Emma Andrus
A dermatology expert panel confirms image-guided superficial radiation therapy as a safe, effective first-line treatment for select nonmelanoma skin cancer cases.
lung cancer | Image credit: Crystal light - stock.adobe.com
March 5th 2025

Study Launches Exploring Peluntamig Combo in DLL3-Expressing Tumors

Jordyn Sava
Dosing has started in a clinical evaluating peluntamig, which targets DLL3 and CD47, combined with chemotherapy in patients with DLL3-expressing small cell lung cancer and neuroendocrine carcinoma.
DNA strand | Image: FreePik
March 4th 2025

Technology, Partnerships, Data, and Culture Are Keys to Bringing Precision Medicine to Community Oncology

Mary Caffrey
First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1
Published: March 4th 2025 | Updated: March 4th 2025

First-Line Tislelizumab Plus Chemotherapy Approved in ESCC Expressing PD-L1

Rose McNulty
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.
Screenshot of an interview with Shaun McKenzie, MD
March 2nd 2025

Identifying Good Candidates for Histotripsy to Treat Liver Tumors

Laura Joszt, MA Shaun P. McKenzie, MD, FACS
Some patients are better candidates than others for histotripsy to treat liver tumors, but ultimately, this treatment still requires a good multidisciplinary team, like any cancer treatment, said Shaun P. McKenzie, MD, FACS.
Karen Winkfield, MD, PhD
March 2nd 2025

Expanding Clinical Trial Access Amid DEI Challenges

Maggie L. Shaw Karen Winkfield, MD, PhD
Karen Winkfield, MD, PhD, addresses the importance of inclusive clinical trial participation and meeting patients where they are.
Screenshot of an interview with Shaun McKenzie, MD
February 27th 2025

Lack of Long-Term Data, Insurance Coverage Impede Adoption of Histotripsy

Laura Joszt, MA Shaun P. McKenzie, MD, FACS
Histotripsy shows promise for treating liver tumors with minimal adverse effects, but limited long-term data and insurance hurdles hinder its adoption, says Shaun P. McKenzie, MD, FACS, of Texas Oncology.
Blue cancer ribbon | Image credit: Chinnapong - stock.adobe.com
February 26th 2025

Cetuximab Plus Chemotherapy May Improve Colorectal Cancer Outcomes

Pearl Steinzor
When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with metastatic colorectal cancer.
Chelsee Jensen, PharmD, BCPS | Image credit: LinkedIn
February 24th 2025

Price Caps During Accelerated Approval Would Help Address Financial Toxicity for Patients, Jensen Says

Chelsee J. Jensen, PharmD, BCPS Interview by Mary Caffrey
Health care institutions with large numbers of Medicare and Medicaid patients may be constrained from offering cancer therapies made available under the accelerated approval pathway.
Cervical cancer awareness | Image Credit: © WhalewithMoon-stock.adobe.com
February 24th 2025

Health System Policy Failures Drive Cervical Cancer Disparities in Rural South

Maggie L. Shaw
The Southern Rural Black Women’s Initiative for Economic and Social Justice works to overcome race, class, cultural, religious, and gender barriers that Black women and young women face in the rural South, specifically the Mississippi Delta and the Black Belt regions of Alabama and Georgia.
Screenshot of an interview with Shaun McKenzie, MD
February 23rd 2025

Histotripsy May Expand Beyond Liver Tumors, but Long-Term Data Are Still Needed

Laura Joszt, MA Shaun P. McKenzie, MD, FACS
Although histotripsy can successfully destroy tumors in the liver, longer-term data are still needed to see recurrence rates and overall survival, said Shaun P. McKenzie, MD, FACS, a surgical oncologist with Texas Oncology.
Screenshot of an interview with Rohan Garje, MD
February 21st 2025

Barriers That Prevent Access to Optimal Treatment in Primary Urethral Cancer

Laura Joszt, MA Rohan Garje, MD
Eligibility issues, a need for better multidisciplinary collaboration, and a lack of incorporation in community practices are all barriers to the use of neoadjuvant chemotherapy followed by surgery for patients with primary urethral cancer, said Rohan Garje, MD.
Susan Escudier, MD, FACP
February 21st 2025

The Need for Payer Support in Overcoming Cancer Care Disparities

Hayden E. Klein Susan Escudier, MD, FACP
Susan Escudier, MD, FACP, discusses the impact of insurance coverage gaps, transportation barriers, and financial hardships on cancer care access and emphasizes the need for payers to better support patients at high risk.
Alicia Morgans MD, MPH | Image credit: Dana-Farber
February 20th 2025

Getting More Doctors to Record a Life-Saving Prostate Cancer Calculation

Mary Caffrey
Accurate calculation of prostate-specific antigen doubling time can be crucial for prostate cancer treatment decisions but is often missed by doctors, impacting patient care.
<12345678
...
187>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo